Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 6/20 | 0.41 |
| ▸ | F2 | P00734 | 5/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6939984 | 0.91 | ROCK2 (0.38) | F10F2ITGB3ITGA2BROCK2 | |
| SCHEMBL7563382 | 0.82 | F2 (0.43) | F10F2ITGB3ITGA2BPRSS1 | |
| Hydrochloric Acid SCHEMBL6937677 | 0.81 | F2 (0.43) | F10F2ITGB3ITGA2BPRSS1 | |
| SCHEMBL7563530 | 0.77 | F10 (0.44) | F10F2ITGB3ITGA2BPRSS1 | |
| Hydrochloric Acid SCHEMBL7566790 | 0.76 | F10 (0.44) | F10F2ITGB3ITGA2BPRSS1 | |
| SCHEMBL2998879 | 0.75 | CYP1A2 (0.36) | F10PRSS1PRSS2PRSS3 | |
| Trifluoroacetic Acid SCHEMBL6941228 | 0.72 | F10 (0.35) | F10F2ITGB3ITGA2BPRSS1 | |
| SCHEMBL6556848 | 0.72 | F10 (0.48) | F10F2ITGB3ITGA2BPRSS1 | |
| Hydrochloric Acid SCHEMBL6554772 | 0.71 | F10 (0.47) | F10F2ITGB3ITGA2BPRSS1 | |
| Hydrochloric Acid SCHEMBL7561461 | 0.71 | ITGB3 (0.40) | F10F2ITGB3ITGA2BPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370540-A1 | ANTI-THROMBOTIC CARBOXYLIC ACID AMIDES, THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-12-17 | — | — | EP | disclosed |
| US-20020183519-A1 | Antithrombotic carboxylic acid amides | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-12-05 | — | — | US | disclosed |
| WO-2002072558-A1 | ANTI-THROMBOTIC CARBOXYLIC ACID AMIDES, THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183519-A1 | Antithrombotic carboxylic acid amides | SERPINC1, TFPI, F2 | F10 33/4885F2 3/4885ITGB3 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.